GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat stomach cancer
Disease control Recruiting nowThis study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …
Matched conditions: GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Immunotherapy plus chemo shows promise against stomach cancer in early trial
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 61 participants will receive the drug combination before and after sur…
Matched conditions: GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC